TScan Therapeutics, Inc.
TCRX
$0.95
-$0.07-6.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.12% | -30.99% | -35.83% | -42.91% | -26.01% |
| Total Depreciation and Amortization | -38.98% | -36.91% | -30.96% | -23.37% | -15.96% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 72.78% | 42.53% | 52.64% | 53.59% | 3.76% |
| Change in Net Operating Assets | 82.85% | -104.57% | -95.98% | -71.29% | -127.22% |
| Cash from Operations | -21.98% | -77.12% | -77.72% | -80.62% | -99.95% |
| Capital Expenditure | -50.44% | -46.71% | -54.40% | -21.58% | 15.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 270.22% | 122.34% | -240.29% | 15.32% | -24.32% |
| Cash from Investing | 256.21% | 112.11% | -216.72% | 13.41% | -21.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.37% | -94.64% | -19.83% | -18.75% | -19.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -77.08% | -77.07% | 70.87% | 71.44% | 39.09% |
| Cash from Financing | -72.24% | -71.22% | 53.26% | 54.13% | 20.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 264.84% | -318.40% | -69.72% | 240.16% | -223.46% |